Tofacitinib als neue Therapieoption für Kinder mit juveniler idiopathischer Arthritis
Crossref DOI link: https://doi.org/10.1007/s15014-022-3953-0
Published Online: 2022-02-11
Published Print: 2022-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kathmann, Wiebke
Text and Data Mining valid from 2022-02-01
Version of Record valid from 2022-02-01
Article History
First Online: 11 February 2022
Free to read: This content has been made available to all.